Avalo CFO sells shares, exercises stock options
Avalo Therapeutics, Inc.'s Chief Financial Officer, Christopher Ryan Sullivan, reported a combination of stock sales and option exercises.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics, Inc.'s Chief Financial Officer, Christopher Ryan Sullivan, reported a combination of stock sales and option exercises. On May 6, 2026, he executed open-market sales totaling 47,000 shares of Avalo Therapeutics common stock in multiple tranches under a Rule 10b5-1 trading plan adopted on November 12, 2025, at prices ranging from $17.95 to $22.88 per share.
On the same date, he exercised stock options to acquire 47,000 common shares at an exercise price of $8.04 per share. Following these transactions, he directly holds 47,423 shares of common stock and 116,000 stock options that are scheduled to vest over time and expire on January 28, 2035.
Insider Trade Summary 10b5-1
Exercise and Sale: 47,000 shares ($571K approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Sullivan Christopher Ryan
Role
Chief Financial Officer
Sold
47,000 shs ($949K)
Approx. gross sale proceeds
$949K
Approx. exercise cost
$378K
Approx. pre-tax spread
$571K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 47,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 47,000 | $8.04 | $378K |
| Sale | Common Stock | 13,834 | $18.5525 | $257K |
| Sale | Common Stock | 12,347 | $19.2835 | $238K |
| Sale | Common Stock | 2,700 | $20.76 | $56K |
| Sale | Common Stock | 9,219 | $21.3698 | $197K |
| Sale | Common Stock | 8,900 | $22.5745 | $201K |
Holdings After Transaction:
Stock Option (Right to Buy) — 116,000 contracts (Direct);
Common Stock — 423 shares (Direct)
Footnotes (7)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
- F2. The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3. The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F4. The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F5. The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F6. The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F7. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Shares sold: 47,000 shares
Sale price range: $17.95–$22.88 per share
Options exercised: 47,000 shares
+5 more
8 metrics
Shares sold
47,000 shares
Total Avalo Therapeutics common stock sold on May 6, 2026
Sale price range
$17.95–$22.88 per share
Price range for multiple open-market sale tranches
Options exercised
47,000 shares
Common shares acquired via stock option exercise on May 6, 2026
Option exercise price
$8.04 per share
Exercise price for the 47,000 stock options converted to common stock
Common shares held
47,423 shares
Direct Avalo Therapeutics common stock holding after transactions
Options remaining
116,000 options
Stock options held after exercise, expiring January 28, 2035
Option expiration
January 28, 2035
Expiration date for remaining stock options at $8.04 exercise price
10b5-1 plan adoption date
November 12, 2025
Date CFO adopted Rule 10b5-1 trading plan governing these trades
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale", "transaction_code_description": "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
""security_title": "Stock Option (Right to Buy)", "transaction_date": "2026-05-06T00:00:00.000Z""
derivative security financial
""transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Avalo Therapeutics (AVTX) report for its CFO?
Avalo Therapeutics reported that CFO Christopher Ryan Sullivan sold 47,000 common shares and exercised stock options for 47,000 shares. The transactions occurred on May 6, 2026 and were disclosed in a Form 4 insider trading report.
Did the Avalo Therapeutics (AVTX) CFO exercise stock options in this Form 4 filing?
Yes. The CFO exercised stock options covering 47,000 shares of Avalo Therapeutics common stock at an exercise price of $8.04 per share. This exercise converted derivative securities into common shares as part of his reported transactions.
What stock option position does the Avalo Therapeutics (AVTX) CFO retain after this Form 4?
Following the reported option exercise, the CFO holds 116,000 stock options with an exercise price of $8.04 per share, expiring on January 28, 2035. The options vest 25% on January 28, 2026, with the remainder vesting in equal monthly installments over three years.
AI-generated analysis. How Rhea-AI works. Not financial advice.
